210 related articles for article (PubMed ID: 24231153)
1. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis.
Sánchez-Solis M; Gartner S; Bosch-Gimenez V; Garcia-Marcos L
Allergol Immunopathol (Madr); 2015; 43(3):298-303. PubMed ID: 24231153
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD
Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
Kua KP; Lee SWH
Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha I; McKoy N
Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
[TBL] [Abstract][Full Text] [Related]
7. Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis.
Metz J; Eber E; Resch B
Pediatr Infect Dis J; 2017 Jun; 36(6):545-548. PubMed ID: 28005688
[TBL] [Abstract][Full Text] [Related]
8. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
Speer ME; Fernandes CJ; Boron M; Groothuis JR
Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007743. PubMed ID: 27439110
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ
Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
[TBL] [Abstract][Full Text] [Related]
11. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
Cochrane Database Syst Rev; 2013 Jun; (6):CD007743. PubMed ID: 23737087
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
Cochrane Database Syst Rev; 2012 Feb; (2):CD007743. PubMed ID: 22336832
[TBL] [Abstract][Full Text] [Related]
13. Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.
Buchs C; Dalphin ML; Sanchez S; Perceval M; Coutier L; Mainguy C; Kassaï-Koupaï B; Reix P
Eur J Pediatr; 2017 Jul; 176(7):891-897. PubMed ID: 28508992
[TBL] [Abstract][Full Text] [Related]
14. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
Winterstein AG; Eworuke E; Xu D; Schuler P
Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089
[TBL] [Abstract][Full Text] [Related]
16. Eligibility for palivizumab prophylaxis in a cohort of children with severe bronchiolitis.
Hasegawa K; Mansbach JM; Piedra PA; Dunn MB; Clark S; Sullivan AF; Camargo CA
Pediatr Int; 2015 Oct; 57(5):1031-4. PubMed ID: 26508190
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections.
Jun S; Sebastianski M; Featherstone R; Robinson J
BMJ Open; 2019 Jul; 9(7):e029832. PubMed ID: 31340973
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
